Cilostazol alleviates white matter degeneration caused by chronic cerebral hypoperfusion in mice: Implication of its mechanism from gene expression analysis. (1st January 2018)

• Record Type: Journal Article
• Authors: Ohtomo, Ryo; Bannai, Taro; Ohtomo, Gaku; Shindo, Akihiro; Tomimoto, Hidekazu; Tsuji, Shoji; Iwata, Atsushi
• Is Part Of: Neuroscience letters. Volume 662(2018)
• Page Start: 247
• Page End: 252
• Publication Date: 2018-01-01
• Subjects: Cilostazol -- Vascular dementia -- White matter disease -- Gene microarray; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2017.10.045
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Long-term administration of cilostazol alleviated white matter degeneration caused by chronic cerebral hypoperfusion. Temporal up-regulation of the genes related to cell development processes was seen in the corpus callosum of BCAS mice. Activation of Btg2 may be one of the major effects of cilostazol towards the white matter during chronic ischemia. Abstract: Cilostazol is known to alleviate white matter demyelination due to chronic cerebral hypoperfusion in rodent models, although their pharmacological mechanisms remain unclear. In this study, we investigated the protective effect of cilostazol in relation to gene expression profile. Bilateral common carotid artery stenosis (BCAS) mice were treated with oral administration of cilostazol or placebo starting from a week after the surgery. Demyelination of the cingulum was compared between the 2 groups 2, 6, and 10 weeks after initial drug administration. Also, to examine temporal gene expression change during demyelination, DNA microarray analysis was conducted using samples from the corpus callosum of 2nd and 6th week BCAS mice. For genes that showed more than 2-fold up-regulation, their increase was validated by qPCR. Finally, to determine the effect of cilostazol towards those genes, their expression in the corpus callosum of 6-week placebo-treated and cilostazol-treated BCAS mice was compared by qPCR. Amelioration of myelin loss was observed in cilostazol-treated group, showing significant difference with those observed in placebo group after 10-week treatment. Gene ontology analysis of the 17 up-regulated (FDR < 0.01) genes showed that majority of the genes were related to cell development processes. Among the validated genes, expression of Btg2 was significantly promoted in the corpus callosum of BCAS mice by administration of cilostazol. Results of this study suggest that activation of Btg2 may be one of the key pharmacological effects of cilostazol towards the white matter during chronic ischemia.